Literature DB >> 30039775

Hospital microbiology laboratory practices for Enterobacteriaceae: Centers for Disease Control and Prevention National Healthcare Safety Network (NHSN) annual survey, 2015 and 2016.

Alicia Shugart1, Maroya Spalding Walters1, Lindsey M Weiner1, David Lonsway1, Alexander J Kallen1.   

Abstract

We analyzed clinical microbiology laboratory practices for detection of multidrug-resistant Enterobacteriaceae in US short-stay acute-care hospitals using data from the National Healthcare Safety Network (NHSN) Annual Facility Survey. Half of hospitals reported testing for carbapenemases, and 1% performed routine polymyxin susceptibility testing using reference broth microdilution.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30039775      PMCID： PMC6346738          DOI： 10.1017/ice.2018.153

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


  2 in total

1.  Policies for Controlling Multidrug-Resistant Organisms in US Healthcare Facilities Reporting to the National Healthcare Safety Network, 2014.

Authors:  Lindsey M Weiner; Amy K Webb; Maroya S Walters; Margaret A Dudeck; Alexander J Kallen
Journal:  Infect Control Hosp Epidemiol       Date:  2016-06-28       Impact factor: 3.254

2.  Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli.

Authors:  Janet A Hindler; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948
  2 in total
  7 in total

1.  Evaluation of the MicroScan Colistin Well and Gradient Diffusion Strips for Colistin Susceptibility Testing in Enterobacteriaceae.

Authors:  Joseph D Lutgring; Anny Kim; Davina Campbell; Maria Karlsson; Allison C Brown; Eileen M Burd
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

2.  Distinctive Features of Ertapenem-Mono-Resistant Carbapenem-Resistant Enterobacterales in the United States: A Cohort Study.

Authors:  Max W Adelman; Chris W Bower; Julian E Grass; Uzma A Ansari; Elizabeth A Soda; Isaac See; Joseph D Lutgring; Jesse T Jacob
Journal:  Open Forum Infect Dis       Date:  2021-12-29       Impact factor: 3.835

Review 3.  The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities.

Authors:  Mark Redell; Glenn S Tillotson
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

4.  Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013-2017.

Authors:  Vikas Gupta; Gang Ye; Melanie Olesky; Kenneth Lawrence; John Murray; Kalvin Yu
Journal:  BMC Infect Dis       Date:  2019-08-23       Impact factor: 3.090

5.  Carbapenemase production among less-common Enterobacterales genera: 10 US sites, 2018.

Authors:  Alicia Shugart; Garrett Mahon; Jennifer Y Huang; Maria Karlsson; Ann Valley; Megan Lasure; Annastasia Gross; Brittany Pattee; Elisabeth Vaeth; Richard Brooks; Tyler Maruca; Catherine E Dominguez; David Torpey; Drew Francis; Rachana Bhattarai; Marion A Kainer; Allison Chan; Heather Dubendris; Shermalyn R Greene; Sara J Blosser; D J Shannon; Kelly Jones; Brenda Brennan; Sopheay Hun; Marisa D'Angeli; Caitlin N Murphy; Maureen Tierney; Natashia Reese; Amelia Bhatnagar; Alex Kallen; Allison C Brown; Maroya Spalding Walters
Journal:  JAC Antimicrob Resist       Date:  2021-09-04

6.  A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011-2020.

Authors:  Michael W Dunne; Steven I Aronin; Kalvin C Yu; Janet A Watts; Vikas Gupta
Journal:  BMC Infect Dis       Date:  2022-02-28       Impact factor: 3.090

7.  Epidemiology of Antimicrobial Resistance Among Blood and Respiratory Specimens in the United States Using Genotypic Analysis From a Cloud-Based Population Surveillance Network.

Authors:  Tristan T Timbrook; Katherine E Olin; Usha Spaulding; Ben W Galvin; Charles B Cox
Journal:  Open Forum Infect Dis       Date:  2022-06-17       Impact factor: 4.423
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.